Skip to main content

ResearchResearch summary

Oral probiotics after vaginal infection in pregnancy

A small pregnancy trial after treated vaginal infection found no clear recurrence benefit; its mixed outcomes do not answer whether probiotics prevent confirmed recurrent VVC.

In this pathway

Current topic
Oral probiotics after vaginal infection in pregnancyCurrent

Page trust and updates

First published
2026-10-08
Evidence as of
2026-10-08
Last updated
2026-10-08
Authorship
Candipedia Research
What changed
Initial summary of a small post-eradication pregnancy trial; its mixed and underpowered outcomes do not establish recurrence prevention or product safety in pregnancy.
Mogana Das Murtey and Patchamuthu Ramasamy, "Saccharomyces cerevisiae, SEM image", licensed under CC BY 3.0

Sources behind these conclusions

Bottom line

This small trial did not establish that oral probiotics prevent vulvovaginal infection during pregnancy. The primary outcome combined abnormal vaginal flora or bacterial vaginosis with vulvovaginal candidiasis (VVC), and the VVC result alone was too imprecise to settle a prevention effect.

Why this source matters

It is a randomized, double-blind comparison of a specific oral probiotic combination with placebo after treatment and smear-confirmed eradication. It adds data from a pregnancy cohort, but not from people selected for confirmed recurrent VVC; its contribution should stay within those limits.

Study and population

The trial took place at three centers in Israel. It enrolled pregnant adults over 18 years old, at up to 30 weeks' gestation, after symptomatic AVF/BV and/or VVC had been treated and a repeat smear showed normal flora. The paper does not establish that participants had confirmed recurrent VVC, and their prior pregnancy infection history was unavailable.

What was tested

Participants took one capsule twice daily until delivery or an identical-looking placebo. Each active capsule contained more than 6 billion CFU of six strains: Bifidobacterium bifidum Bb-06, B. lactis Bi-07, Lactobacillus acidophilus La-14, Lacticaseibacillus paracasei Lpc-37, L. rhamnosus Lr-32, and Streptococcus thermophilus St-21. This is evidence about that combination and schedule, not every probiotic product.

Results

At least one VVI occurred in 16/24 (67%) participants assigned probiotic and 11/23 (48%) assigned placebo (p=0.19). This primary composite included AVF/BV and VVC. VVC separately occurred in 11/24 (46%) and 9/23 (39%) (p=0.64); the paper reported no confidence interval for that difference. At study end, pruritus was reported by 3/24 (13%) versus 9/23 (39%) (p=0.03), the only significant symptom comparison among multiple comparisons; the authors said chance could explain it. Gastrointestinal adverse effects were 4/24 (17%) versus 2/23 (9%) (p=0.67).

Applicability

These results concern pregnant participants after a treated and eradicated episode of AVF/BV and/or VVC, using one six-strain oral product until delivery. They do not establish an effect in people with confirmed recurrent VVC, whose recurrence history was not defined, or in nonpregnant people. The trial also did not test probiotics for acute treatment, as a replacement for antifungals, or as a class.

Limitations

The trial planned 68 participants, described 50 as recruited, and analyzed 47; its flow diagram does not explain the difference. Low eligibility and exhausted resources led to early stopping. The mixed primary outcome and small VVC subgroup leave substantial uncertainty. Follow-up varied with delivery, average exposure differed between groups, and maternal and neonatal outcomes were too sparse to establish safety or exclude meaningful differences. The isolated pruritus result may be chance.

Contribution to the evidence

Contextual. The trial adds a randomized estimate for one probiotic combination after eradication in pregnancy. Its composite outcome, small VVC subgroup, early stop, and lack of a defined RVVC population mean it does not establish prevention benefit, no effect, equivalence, or a broader probiotic conclusion.

Practical change

No practical change. This trial does not support choosing this product to prevent recurrent VVC or replacing condition-specific assessment or established treatment. It also cannot establish the product's safety in pregnancy; follow current local product and care guidance.

Funding and conflicts

The Altman Research Institute provided a grant that also included the study products. The authors declared no conflicts of interest.

Source

Read the original publication (published 27 January 2025; Nutrients 2025;17(3):460).

Study type, population, and sample scale

Study type
Multicenter randomized, double-blind, placebo-controlled trial
Population
Pregnant adults over 18 years old, enrolled by 30 weeks' gestation in three Israeli centers after treatment of symptomatic abnormal vaginal flora or bacterial vaginosis and/or vulvovaginal candidiasis (VVC), with a follow-up smear showing eradication. Prior pregnancy infection history was unavailable; participants were not selected for confirmed recurrent VVC.
Sample scale
50 women were recruited against a target of 68; 47 were analyzed, 24 assigned probiotic and 23 placebo. The paper's flow diagram does not explain the gap between 50 recruited and 47 analyzed.
Read the original source

Results

  • At least one vulvovaginal infection (VVI) during follow-up occurred in 16/24 (67%) probiotic participants and 11/23 (48%) placebo participants (p=0.19). The primary composite included abnormal vaginal flora or bacterial vaginosis (AVF/BV) as well as VVC; it was not a VVC-only outcome.
  • VVC reported separately occurred in 11/24 (46%) probiotic participants and 9/23 (39%) placebo participants (p=0.64). This was a small secondary subgroup; no confidence interval for this difference was reported.
  • Mean study exposure was 15.4 ± 5.6 weeks with probiotic and 12.4 ± 4.2 weeks with placebo (p=0.07); mean adherence was 81 ± 27% and 81 ± 24%, respectively (p=0.89).
  • At study end, pruritus was reported by 3/24 (13%) probiotic participants and 9/23 (39%) placebo participants (p=0.03). This was the only significant symptom difference among multiple comparisons, and the authors noted it might be due to chance.
  • Gastrointestinal adverse effects were reported by 4/24 (17%) probiotic participants and 2/23 (9%) placebo participants (p=0.67). These small counts and the underpowered maternal and neonatal outcomes cannot establish pregnancy safety or rule out meaningful differences.

Limitations

The study analyzed 47 participants despite a planned target of 68; 50 were described as recruited, and the flow diagram does not reconcile all recruited participants with the analyzed groups.
Early stopping for low eligibility and exhausted resources left the trial underpowered. It cannot exclude clinically meaningful benefit or harm, or establish equivalence or no effect.
The primary endpoint combined AVF/BV and VVC, while VVC alone occurred in 11/24 versus 9/23 participants.
This small secondary VVC subgroup, without a reported confidence interval, cannot establish a VVC-specific prevention effect.
Participants entered after one symptomatic vaginal infection had been treated and eradication was confirmed; prior pregnancy VVI history was unavailable.
The study did not establish confirmed recurrent VVC or a participant's recurrence history, so its results cannot answer whether probiotics prevent RVVC.
Follow-up ended at delivery, with different mean exposure durations and a baseline difference in gestational week between groups.
The study assessed a variable post-eradication period, not a standardized long-term recurrence-free outcome.
Pregnancy, maternal, and neonatal event counts were small; gastrointestinal adverse effects were 4/24 versus 2/23 (p=0.67).
The trial was not powered to establish product safety in pregnancy or exclude meaningful maternal or infant outcome differences.
Pruritus at study end differed at p=0.03 among multiple symptom and time-point comparisons.
It was the sole significant symptom difference; the authors noted chance as a possible explanation, so it is exploratory and not evidence of VVC prevention.

Applies to

  • The studied six-strain oral product, taken twice daily after a successfully treated symptomatic vaginal infection in pregnant participants and continued until delivery.
  • A narrow pregnancy cohort with prior AVF/BV and/or VVC, whose follow-up outcome included both AVF/BV and VVC.

Does not apply to

  • People with microbiologically confirmed recurrent VVC; the trial did not define or recruit an RVVC population, and prior pregnancy infection history was unavailable.
  • Nonpregnant people, probiotics as a class, other products or strains, other doses, or different routes.
  • Treating an acute infection, replacing antifungal treatment, or assuring that this product is safe in pregnancy.

Contribution to the current conclusion

Contextual

This small underpowered trial adds a randomized estimate for one six-strain product used after eradication in pregnancy. Its primary outcome combined abnormal flora, bacterial vaginosis, and VVC, while the VVC subgroup was small; participants did not have defined confirmed recurrent VVC. The results therefore add context about a distinct population and do not establish prevention benefit, no effect, equivalence, or a practical change.

Related evidence map

Practical change or no change

No practical change. This underpowered study of a specific product in a narrow pregnancy cohort does not establish prevention benefit, prove no effect, or support probiotics as a substitute for evaluation or established treatment. It also cannot establish product safety in pregnancy; use current local product and care guidance.

Funding and conflicts

Funding
A grant from the Altman Research Institute also included the study products.
Conflicts
All authors declared no conflicts of interest.
Paper date
2025-01-27

Sources

View all 1 source